An essential resource for R&D professionals and clinicians with an interest in biologic therapies.BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
对生物治疗感兴趣的研发专业人员和临床医生的重要资源。 《生物药物》涵盖了基于生物技术的药物和诊断产品的开发和治疗应用，用于治疗人类疾病。 《生物药物》提供了一系列额外的增强功能，旨在提高期刊内容的可见性、读者群和教育价值。每篇文章都附有一个要点摘要，为广大读者提供了一个省时的内容概述。文章可能附有简明的语言摘要，以帮助患者、护理人员和其他人理解重要的医学进展。该杂志还提供了包括各种其他类型的增强功能的选项，包括幻灯片集、视频和动画。所有增强功能都经过同行评审，达到与文章本身相同的高标准。同行评审使用Editorial Manager® 进行，并由国际专家数据库提供支持。此数据库与其他Adis期刊共享。
The Therapeutic Potential of Nanobodies
来源期刊：BiodrugsDOI：10.1007/s40259-019-00392-z
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
来源期刊：BiodrugsDOI：10.1007/s40259-019-00333-w
Oncolytic Viruses: Priming Time for Cancer Immunotherapy
来源期刊：BiodrugsDOI：10.1007/s40259-019-00367-0
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
来源期刊：BiodrugsDOI：10.1007/s40259-019-00370-5
Evolution of the EU Biosimilar Framework: Past and Future
来源期刊：BiodrugsDOI：10.1007/s40259-019-00377-y
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
来源期刊：BiodrugsDOI：10.1007/s40259-019-00368-z
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review
来源期刊：BioDrugsDOI：10.1007/s40259-019-00347-4
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
来源期刊：BiodrugsDOI：10.1007/s40259-019-00394-x
Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
来源期刊：BiodrugsDOI：10.1007/s40259-019-00344-7
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
来源期刊：BiodrugsDOI：10.1007/s40259-019-00350-9
CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms
来源期刊：BioDrugsDOI：10.1007/s40259-019-00384-z
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
来源期刊：BioDrugsDOI：10.1007/s40259-019-00355-4
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
来源期刊：BiodrugsDOI：10.1007/s40259-019-00345-6
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
来源期刊：BiodrugsDOI：10.1007/s40259-019-00362-5
Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries
来源期刊：BioDrugsDOI：10.1007/s40259-019-00359-0
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
来源期刊：BioDrugsDOI：10.1007/s40259-019-00382-1
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
来源期刊：BiodrugsDOI：10.1007/s40259-019-00363-4
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis
来源期刊：BioDrugsDOI：10.1007/s40259-019-00376-z
An Efficient Development Paradigm for Biosimilars
来源期刊：BiodrugsDOI：10.1007/s40259-019-00371-4
PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
来源期刊：BiodrugsDOI：10.1007/s40259-019-00343-8
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics
来源期刊：BioDrugsDOI：10.1007/s40259-019-00389-8
Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis
来源期刊：BioDrugsDOI：10.1007/s40259-019-00356-3
Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar
来源期刊：BioDrugsDOI：10.1007/s40259-019-00349-2
A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males
来源期刊：BioDrugsDOI：10.1007/s40259-019-00340-x
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
来源期刊：BiodrugsDOI：10.1007/s40259-019-00393-y
Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
来源期刊：BioDrugsDOI：10.1007/s40259-019-00358-1
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar
来源期刊：BioDrugsDOI：10.1007/s40259-019-00334-9
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
来源期刊：BiodrugsDOI：10.1007/s40259-019-00373-2
Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
来源期刊：BioDrugsDOI：10.1007/s40259-019-00357-2
Steady-State Plasma Concentrations of Polyethylene Glycol (PEG) are Reached in Children and Adults During Once-Weekly Prophylactic Treatment with Nonacog Beta Pegol (N9-GP)
来源期刊：BiodrugsDOI：10.1007/s40259-019-00380-3
Biosimilars: A Value Proposition
来源期刊：BioDrugsDOI：10.1007/s40259-019-00360-7
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks
来源期刊：BioDrugsDOI：10.1007/s40259-019-00369-y
Comment on: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
来源期刊：BioDrugsDOI：10.1007/s40259-019-00383-0
Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
来源期刊：BiodrugsDOI：10.1007/s40259-019-00353-6
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
来源期刊：BiodrugsDOI：10.1007/s40259-019-00381-2
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
来源期刊：BioDrugsDOI：10.1007/s40259-019-00366-1
Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis
来源期刊：BioDrugsDOI：10.1007/s40259-019-00378-x
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study
来源期刊：BioDrugsDOI：10.1007/s40259-019-00385-y
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
来源期刊：BiodrugsDOI：10.1007/s40259-019-00375-0
LA-EP2006: A Pegfilgrastim Biosimilar
来源期刊：BioDrugsDOI：10.1007/s40259-019-00348-3
Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals
来源期刊：BiodrugsDOI：10.1007/s40259-019-00341-w
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy
来源期刊：BioDrugsDOI：10.1007/s40259-019-00365-2
Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product
来源期刊：BiodrugsDOI：10.1007/s40259-019-00386-x
Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”
来源期刊：BioDrugsDOI：10.1007/s40259-019-00379-w
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
来源期刊：BiodrugsDOI：10.1007/s40259-019-00390-1
In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage
来源期刊：BioDrugsDOI：10.1007/s40259-019-00336-7
Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study
来源期刊：BioDrugsDOI：10.1007/s40259-019-00396-9
Delivering on the Promise of Biosimilars
来源期刊：BioDrugsDOI：10.1007/s40259-019-00388-9
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
来源期刊：BiodrugsDOI：10.1007/s40259-019-00374-1
Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity
来源期刊：BioDrugsDOI：10.1007/s40259-019-00391-0
